Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEL001 in advanced solid tumors
NCT07259889Phase 1Recruiting
- Sponsor
- Xiling Lab
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CEL001 in solid tumor (advanced stage), sponsored by Xiling Lab. Primary endpoint: Treatment related adverse events and serious adverse events at 2 years. Started Jun 2025; status: recruiting.
02
Drugs
CEL001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07259889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259889.